Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Parkinson's disease in the acute hospital

Sion L Jones and John V Hindle
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.11-1-84
Clin Med February 2011
Sion L Jones
School of Medical Sciences University of Bangor Llandudno Hospital
Roles: ST5 trainee in geriatric medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John V Hindle
School of Medical Sciences University of Bangor Llandudno Hospital
Roles: Consultant geriatrician and clinical senior lecturer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: j.v.hindle@bangor.ac.uk
  • Article
  • Figures & Data
  • Info & Metrics
Loading
Key Words
  • delirium
  • dysphagia
  • falls
  • Parkinson's disease
  • palliative

Key points

Avoid abrupt withdrawal of antiparkinsonian therapy

Be alert to the possibility of Parkinsonism-hyperpyrexia syndrome

Seek early specialist help

Parkinson's disease (PD) is the second most common neurodegenerative disease, with a prevalence of 1.8 per 100 in people aged 65 or over in Europe.1 Historically, it has been regarded as a motor condition characterised by rigidity, bradykinesia and tremor. Increasingly, however, non-motor complications of the disease, such as depression, dementia and autonomic dysfunction, are being recognised as significant contributors to morbidity.

Parkinson's disease medications: ‘get it on time’

Medication concordance is a fundamental part of the management of PD. A vicious cycle of dysphagia and difficulties with drug delivery can be initiated by:

  • failure to prescribe usual medications at the correct times

  • inflexible timing of drug rounds

  • injudicious application of nil by mouth (NBM) orders.

Falls, fractures and aspiration pneumonia are potential complications. One study found that medications were omitted or prescribed inappropriately in 74% of emergency admissions of PD patients,2 61% of whom developed significant sequelae including a hip fracture and admission to intensive therapy unit with severe akinesia. The National Institute for Health and Clinical Excellence guidelines for PD advocate self-medication as a strategy to circumvent this problem.3 The Parkinson's UK ‘get it on time’ campaign promotes medication concordance by providing checklists and an audit toolkit which are available online.4

Swallowing

On objective assessment, nearly all PD patients have some degree of swallowing dysfunction,5 although this may become apparent only as the disease progresses.6 Clinicians should be alert to the possibility of aspiration pneumonia. Often the only clue may be a temperature rise and oxygen denaturation.

Management

The management of dysphagia includes early referral for speech and language therapy assessment and/or multidisciplinary swallowing assessment (Fig 1). Referral for percutaneous endoscopic gastrostomy (PEG) feeding is rarely required in idiopathic PD and should be considered only as a last resort.7 Swallowing problems are less pronounced in dyskinetic patients,8 indicating a degree of responsiveness to levodopa and emphasising the need to maintain delivery of PD medications. If possible, PD patients in the later stage of the disease should be encouraged to eat during ‘on’ periods. Novel routes of drug administration may need to be sought. Co-careldopa (Madopar®) is available in soluble form and a nasogastric tube can provide a temporary solution for the provision of PD therapy.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Management of the dysphagic Parkinson's disease (PD) patient. NBM = nil by mouth; NG = nasogastric; SLT = speech and language therapy. (Adapted from the Parkinson's Disease Nurse Specialist Association website).

Rotigotine. A non-ergot dopamine agonist, rotigotine, is available as a 24-hour transdermal patch. Although initially developed as a therapy for early stage PD, its utility in dysphagic or NBM hospital patients is being increasingly recognised. One case report describes its use in an akinetic crisis in a patient in whom amantadine and apomorphine were contraindicated.9 Its ease of administration and relatively uncomplicated switch over from the oral to transdermal route makes it an attractive option in elective abdominal surgery where interruption of enteral delivery of medications is inevitable.10

Anaesthesia. Patients with PD require detailed assessment before anaesthesia11 because PD can cause respiratory, autonomic, cardiovascular and gastrointestinal problems which may interfere with anaesthesia. Management is particularly challenging due to potential drug interactions and the need to avoid cessation of PD treatments (Fig 2). Parkinson's UK website provides a helpful information sheet for patients undergoing anaesthesia.12

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Maintaining Parkinson's disease (PD) drug therapy during perioperative period (not including patients with deep brain stimulation). NG = nasogastric.

Parkinsonism-hyperpyrexia syndrome

Clinically indistinguishable from neuroleptic malignant syndrome (NMS), the rare but potentially fatal condition of parkinsonism-hyperpyrexia syndrome is characterised by rigidity, hyperpyrexia and stupor (Fig 3).13 It is usually precipitated by abrupt withdrawal or malabsorption of levodopa14,15 but can arise secondary to triggers such as infection or anaemia.16 The condition is characterised by a sustained unresponsiveness to dopamine or dopaminergic therapy which may last days to weeks and must not be interpreted as treatment failure.14 In most cases, muscle enzymes will be significantly elevated.

Fig 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 3.

Clinical features and management of the parkinsonism-hyperpyrexia syndrome. CK = creatine kinase; DIC = disseminated intravascular coagulation. Reproduced with the kind permission of Dr Donald Grosset.

Management

Basic supportive care includes intravenous (iv) hydration, temperature control and thromboprophylaxis. Mechanical ventilation may be necessary. As in NMS, dantrolene can be used to treat rigidity and hyperpyrexia (Fig 3).13 Although not established treatments, iv steroids17 and electroconvulsive therapy18 have also been successfully used. Dopaminergic replacement therapy is the mainstay of treatment by nasogastric levodopa administration, continuous subcutaneous administration of the dopamine agonist apomorphine or a combination of both.19 Apomorphine must be given under expert supervision: it is a powerful emetic and prior loading with domperidone (20 mg tds orally or 60 mg tds rectally) is vital.

Falls

Falls in PD are usually multifactorial in origin. Postural instability is common with advancing disease as are visuospatial deficits and orthostatic hypotension. Executive dysfunction is also prevalent in PD and associated with an increased risk of falling.20 Fracture risk should be quantified and initiation of bone protection considered. Medication review should aim to identify common culprit medications such as benzodiazepines. Dopaminergic agents can exacerbate postural hypotension, but considered assessment is required before hastily reducing medications.

Management

The management of orthostatic hypotension involves non-pharmacological measures such as advice on hydration, avoiding rapid positional changes and compression stockings. Pharmacological therapies such as fludrocortisone are also used.21 The evidence for physiotherapy in reduction of falls in late-stage PD is limited, but involvement of physiotherapists and occupational therapists is essential in promoting confidence and managing a safe discharge from hospital.

Dyskinesias

Dyskinesias affect approximately 40% of patients and are pathognomic of advancing PD. Occasionally patients present to acute units with severe dyskinesia. This is rarely life-threatening but can cause considerable distress and weight loss, with rhabdomyolysis and raised muscle enzymes rare complications.22 Non-PD specialist clinicians may mistakenly tell patients that they are ‘overtreated’ because of their dyskinesia or hallucinations, an inappropriate explanation which can cause distress to patients.

Management

A very graduated reduction in dopaminergic therapy may help reduce dyskinesias but can exacerbate ‘off’ periods. Oral amantadine (100 mg 2–4 times daily) may reduce dyskinesias, but is perhaps limited by its anticholinergic side effects and subsequent risk of delirium and psychosis, especially in older people.23 Introduction of long-acting dopamine agonists or continuous subcutaneous apomorphine with a reduction in levodopa dose may help over a period of months but will not be helpful in the acute setting.

Neuropsychiatric complications

Neuropsychiatric complications of PD are common. In one cohort studied over 15–18 years, 84% developed cognitive decline, with 48% satisfying the criteria for dementia and 50% reporting hallucinations.24 Hallucinations and psychosis are due to a mixture of the cognitive, visuospatial and neurochemical changes of the disease itself combined with the effects of dopaminergic drugs.25 In the acute setting, a reversible precipitating cause for delirium such as infection or electrolyte disturbance should first be sought.

Management

Neuroleptic drugs such as haloperidol should be avoided in the agitated patient as they can exacerbate the motor features of PD. If it is absolutely necessary to use sedation in severe agitation, a short-acting benzodiazepine such as lorazepam is preferred.

Delirium or psychosis may be associated with the introduction of a new antiparkinsonian medication. A graduated withdrawal of therapy may then be required and a ‘last in, first out’ approach is logical. Under expert supervision, drugs commonly implicated in the development of psychosis, such as anticholinergics, selegiline and amantadine, should be withdrawn first.25 The atypical neuroleptic clozapine is particularly effective in psychosis in PD,26 but is not appropriate in the acute setting due to strict licensing restrictions relating to the small risk of fatal agranulocytosis. Quetiapine in small doses (25–50 mg) is used widely as it is felt to be safer than other atypical neuroleptics, but the evidence to support its use is limited. It may be that much of its effect is due to sedation, which can be a limiting side effect in older people. There is evidence that it is associated with a similar increased mortality risk in people with dementia to that reported with other atypical neuroleptics.27

Admission with delirium may herald the onset of dementia; once stabilised, the patient should be evaluated for a fixed cognitive deficit. Rivastigmine, a cholinesterase inhibitor given orally (1.5 mg bd initially) or as a transdermal patch (4.6 mg/24h), has been shown to confer modest benefits in terms of cognitive function28 and may ameliorate symptoms of psychosis and hallucinosis.

Complex treatments

Increasing numbers of PD patients are undergoing complex treatments such as deep brain stimulation (DBS) implants or Duodopa® therapy.

Deep brain stimulation implants

Patients with DBS implants in situ usually present to the emergency department with problems that are not directly related to this treatment. For example, in a recent study mental changes were the most common presentation of patients with DBS for PD.29 Very rarely, patients with DBS can present with lead erosion, equipment infection or battery failure leading to severe rebound akinesia. In these circumstances it is essential to seek urgent specialist advice. Patients requiring anaesthesia with DBS in place should be discussed with a specialist centre.

Duodopa

Duodopa® therapy involves intrajejunal gel infusion of levodopa administered through a modified PEG tube. Once established, most complications are likely to be technical problems with the tube such as displacement or blockage. This also requires specialist advice.30

End of life

Most patients with PD die in hospital.31 Although traditionally palliative care teams have not managed PD patients, their value in managing the later stages of the disease is increasingly recognised. The emotional needs of affected patients and their care givers are similar to those with malignant conditions.32 Pain is an underrecognised symptom, affecting 40% of patients. Rigidity and immobility can be distressing and painful. Continuation of antiparkinsonian therapy is likely to improve symptom control at the end of life. The rotigotine patch33 and subcutaneous apomorphine34 have been used in dysphagic patients in the palliative setting. Taking food and fluid orally provides benefits beyond biological usefulness.7 A pragmatic approach to oral feeding in the dysphagic patient at the end of life should be employed.

Conclusions

Most patients are not admitted to hospital acutely with PD as their primary diagnosis.35 Consequently the team responsible for the acute care will comprise non-PD specialists. A working knowledge of PD is therefore important across specialties, particularly an awareness of the potentially catastrophic consequences of drug withdrawal. Managing the interface between symptom control and drug side effects can be complex and challenging, particularly in the acutely ill patient. It is important to liaise with PD nurses and/or specialist PD physicians in the management of the condition in the acute setting. Perhaps most important of all is to listen closely to the patients who are often expert and well informed by the cumulative experience gained from living with the disease.

  • Royal College of Physicians

References

  1. ↵
    1. de Rijk MC,
    2. Launer LJ,
    3. Berger K,
    4. et al.
    Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(Suppl 5):S21–3
    OpenUrlPubMed
  2. ↵
    1. Magdalinou KN,
    2. Martin A,
    3. Kessel B
    Prescribing medications in Parkinson's disease (PD) patients during acute admissions to a District General Hospital. Parkinsonism Relat Disord 2007;13:539–40doi:10.1016/j.parkreldis.2006.11.006
    OpenUrlCrossRefPubMed
  3. ↵
    1. National Institute for Health and Clinical Excellence
    . Parkinson's disease. National clinical guideline for diagnosis and management in primary and secondary care. London: NICE, 2006.
  4. ↵
    Going into hospital, www.parkinsons.org.uk/advice/publications/going_into_hospital.aspx.
  5. ↵
    1. Potulska A,
    2. Friedman A,
    3. Królicki L,
    4. Spychala A
    Swallowing disorders in Parkinson's disease. Parkinsonism Relat Disord 2003;9:349–53doi:10.1016/S1353-8020(03)00045-2
    OpenUrlCrossRefPubMed
  6. ↵
    1. Edwards LL,
    2. Quigley EM,
    3. Pffeifer RF
    Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992;42:726–32doi:10.1212/WNL.42.4.726
    OpenUrlFREE Full Text
  7. ↵
    1. Royal College of Physicians
    Oral feeding difficulties and dilemmas. A guide to practical care, particularly towards the end of life. London: RCP, 2010. Report of a Working Party
  8. ↵
    1. Monte FS,
    2. da Silva-Júnior FP,
    3. Braga-Neto P,
    4. Nobre e Souza MA,
    5. de Bruin VM
    Swallowing abnormalities and dyskinesia in Parkinson's disease. Mov Disord 2005;20:457–62doi:10.1002/mds.20342
    OpenUrlCrossRefPubMed
  9. ↵
    1. Dafotakis M,
    2. Sparing R,
    3. Juzek A,
    4. Block F,
    5. Kosinski CM
    Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis. J Clin Neurosci 2009;16:335–7doi:10.1016/j.jocn.2008.02.015
    OpenUrlPubMed
  10. ↵
    1. Korczyn AD,
    2. Reichmann H,
    3. Boroojerdi B,
    4. Häck HJ
    Rotigotine transdermal system for perioperative administration. J Neural Transm 2007;114:219–21doi:10.1007/s00702-006-0606-3
    OpenUrlCrossRefPubMed
  11. ↵
    1. Nicholson G,
    2. Pereira AC,
    3. Hall GM
    Parkinson's disease and anaesthesia. Br J Anaesth 2002;89:904–16doi:10.1093/bja/aef268
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Anaesthesia and Parkinson's, www.parkinsons.org.uk/pdf/FS36_AnaesthesiaandParkinsons.pdf.
  13. ↵
    1. Newman EJ,
    2. Grosset DG,
    3. Kennedy PG
    The parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009;10:136–40doi:10.1007/s12028-008-9125-4
    OpenUrlCrossRefPubMed
  14. ↵
    1. Onofrj M,
    2. Thomas A
    Acute akinesia in Parkinson disease. Neurology 2005;64:1162–9doi:10.1212/01.WNL.0000157058.17871.7B
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Takubo H,
    2. Harada T,
    3. Hashimoto T,
    4. et al.
    A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 2003;9(Suppl 1):S31–41doi:10.1016/S1353-8020(02)00122-0
    OpenUrlCrossRefPubMed
  16. ↵
    1. Tackenberg B,
    2. Möller JC,
    3. Eggert K,
    4. Sommer N,
    5. Oertel WH
    Akinetic crisis caused by rectus sheath hematoma and acute anaemia due to subcutaneous administration of apomorphine. Mov Disord 2006;21:126–7doi:10.1002/mds.20716
    OpenUrlPubMed
  17. ↵
    1. Sato Y,
    2. Asoh T,
    3. Metoki N,
    4. Satoh K
    Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:574–6doi:10.1136/jnnp.74.5.574
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Meagher LJ,
    2. McKay D,
    3. Herkes GK,
    4. Needham M
    Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy. J Clin Neurosci 2006;13:857–9doi:10.1016/j.jocn.2005.09.017
    OpenUrlCrossRefPubMed
  19. ↵
    1. Thomas A,
    2. Iacono D,
    3. Luciano AL,
    4. Armellino K,
    5. Onofrj M
    Acute akinesia or akinetic crisis in Parkinson's disease. Neurol Sci 2003;24:219–20doi:10.1007/s10072-003-0139-6
    OpenUrlCrossRefPubMed
  20. ↵
    1. Allcock LM,
    2. Rowan EN,
    3. Steen IN,
    4. et al.
    Impaired attention predicts falling in Parkinson's disease. Parkinsonism Relat Disord 2009;15:110–5doi:10.1016/j.parkreldis.2008.03.010
    OpenUrlCrossRefPubMed
  21. ↵
    1. Mostile G,
    2. Jankovic J
    Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S224–32doi:10.1016/S1353-8020(09)70820-X
    OpenUrlCrossRefPubMed
  22. ↵
    1. Pozzoni P,
    2. Tentori F,
    3. Corti M,
    4. Pozzi C
    Rhabdomyolysis as a complication of Parkinson's disease. G Ital Nefrol 2002;19:13–7 [In Italian]
    OpenUrlPubMed
  23. ↵
    1. Jankovic J,
    2. Stacy M
    Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21:677–92doi:10.2165/00023210-200721080-00005
    OpenUrlCrossRefPubMed
  24. ↵
    1. Hely MA,
    2. Morris JG,
    3. Reid WG,
    4. Trafficante R
    Sydney Multicenter Study of Parkinson's disease: non-L-dopa responsive problems dominate at 15 years. Mov Disord 2005;20:190–9doi:10.1002/mds.20324
    OpenUrlCrossRefPubMed
  25. ↵
    1. Hindle J,
    2. Playfer J
    . Parkinson's disease in the older patient 2008 2nd edn. Oxford: Radcliffe Publishing
  26. ↵
    1. Pollak P,
    2. Tison F,
    3. Rascol O,
    4. et al.
    Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689–95doi:10.1136/jnnp.2003.029868
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Schneider LS,
    2. Dagerman KS,
    3. Insel P
    Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934–43doi:10.1001/jama.294.15.1934
    OpenUrlCrossRefPubMed
  28. ↵
    1. Emre M,
    2. Aarsland D,
    3. Albanese A,
    4. et al.
    Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509–18doi:10.1056/NEJMoa041470
    OpenUrlCrossRefPubMed
  29. ↵
    1. Resnick AS,
    2. Foote KD,
    3. Rodriguez RL,
    4. et al.
    The number and nature of emergency department encounters in patients with deep brain stimulators. J Neurol 2010;257:122–31 [Erratum: J Neurol 2010;257:158–9]
    OpenUrlPubMed
  30. ↵
    1. Devos D
    French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993–1000
    OpenUrlCrossRefPubMed
  31. ↵
    1. Snell K,
    2. Pennington S,
    3. Lee M,
    4. Walker R
    The place of death in Parkinson's disease. Age Ageing 2009;38:617–9doi:10.1093/ageing/afp123
    OpenUrlFREE Full Text
  32. ↵
    1. Hudson PL,
    2. Toye C,
    3. Kristjanson LJ
    Would people with Parkinson's disease benefit from palliative care?. Palliat Med 2006;20:87–94doi:10.1191/0269216306pm1108oa
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Christie J
    The use of transdermal rotigotine in a patient with advanced Parkinson's disease and dysphagia. Palliat Med 2007;21:163–4
    OpenUrlPubMed
  34. ↵
    1. Dewhurst F,
    2. Lee M,
    3. Wood B
    The pragmatic use of apomorphine at the end of life. Palliat Med 2009;23:777–9doi:10.1177/0269216309106979
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Woodford H,
    2. Walker R
    Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord 2005;20:1104–8doi:10.1002/mds.20485
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Parkinson's disease in the acute hospital
Sion L Jones, John V Hindle
Clinical Medicine Feb 2011, 11 (1) 84-88; DOI: 10.7861/clinmedicine.11-1-84

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Parkinson's disease in the acute hospital
Sion L Jones, John V Hindle
Clinical Medicine Feb 2011, 11 (1) 84-88; DOI: 10.7861/clinmedicine.11-1-84
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Parkinson's disease medications: ‘get it on time’
    • Swallowing
    • Parkinsonism-hyperpyrexia syndrome
    • Falls
    • Dyskinesias
    • Neuropsychiatric complications
    • Complex treatments
    • End of life
    • Conclusions
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • CME Medical Masterclass (122612): self-assessment ­questionnaire
  • CME Genetic medicine (113042) self-assessment questionnaire
  • The emergence of sarcopenia as an important entity in older people
Show more CME Geriatric Medicine

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians